Storage iron exchange in the rat as affected by deferoxamine

Area of Science:

• Iron metabolism
• Hepatocyte and reticuloendothelial cell function
• Chelation therapy

Background:

• Understanding iron distribution is crucial for managing iron overload and deficiency disorders.
• Radioactive iron tracers allow detailed tracking of iron localization and movement in vivo.
• Deferoxamine (DFO) is a chelating agent used to treat iron overload.

Purpose of the Study:

• To determine the initial tissue localization and redistribution of intravenously injected radioactive iron in rats.
• To investigate the effect of deferoxamine (DFO) on iron redistribution in various physiological states.
• To elucidate the mechanisms of DFO action on iron stores and excretion.

Main Methods:

• Intravenous injection of radioactive iron (as ferritin, nonviable red cells, or chondroitin sulfate) into rats.
• Analysis of iron localization and redistribution in hepatocytes and reticuloendothelial cells over time.
• Administration of deferoxamine (DFO) to iron-deficient, normal, iron-loaded, and phenylhydrazine-treated rats.

Main Results:

• Ferritin iron primarily localized to hepatocytes with minimal redistribution in normal rats.
• Iron was actively released from reticuloendothelial cells after injection of nonviable red cells or chondroitin sulfate.
• All iron forms were mobilized in iron-deficient animals.
• DFO extensively chelated hepatocyte iron, reducing its availability for erythropoiesis.
• DFO showed minimal chelation of reticuloendothelial cell-processed iron, with little impact on red cell production.
• Urinary chelate iron correlated with the animal's iron load, not erythropoiesis.

Conclusions:

• DFO primarily acts on hepatocyte iron stores, facilitating excretion via the intestinal tract.
• A secondary site of DFO action, possibly at the hepatocyte membrane, leads to urinary iron excretion.
• DFO does not appear to act directly on the reticuloendothelial cell for iron chelation.